Signal integration: A framework for understanding the efficacy of therapeutics targeting the human EGFR family

Journal of Clinical Investigation

Volumn 118, Issue 11, 2008, Pages 3574-3581

  Shepard, H Michael ^a   Brdlik, Cathleen M ^a   Schreiber, Hans ^b  

^a Receptor BioLogix Inc   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; G PROTEIN COUPLED RECEPTOR; HYBRID PROTEIN; INTEGRIN; MONOCLONAL ANTIBODY; PERTUZUMAB; RB 200; TOLL LIKE RECEPTOR; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; AUTOCRINE EFFECT; BREAST CANCER; DRUG EFFECT; DRUG TARGETING; EPITHELIUM TUMOR; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 55849126233     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI36049     Document Type: Review

References (117)

1. DeNardo, D.G., and Coussens, L.M. 2007. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 9:212.
2. Johansson, M., DeNardo, D.G., and Coussens, L.M. 2008. Polarized immune responses differentially regulate cancer development. Immunol. Rev. 222:145-154.
3. Tlsty, T.D., and Coussens, L.M. 2006. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. 1:119-150.
4. Hanahan, D., and Weinberg, R.A. 2000. The hallmarks of cancer. Cell. 100:57-70.
5. Nowell, P.C. 1986. Mechanisms of tumor progression. Cancer Res. 46:2203-2207.
6. Sporn, M.B., and Todaro, G.J. 1980. Autocrine secretion and malignant transformation of cells. N. Engl. J. Med. 303:878-880.
7. Baselga, J. 2006. Targeting tyrosine kinases in cancer: the second wave. Science. 312:1175-1178.
8. Zhang, H., et al. 2007. ErbB receptors: from oncogenes to targeted cancer therapies. J. Clin. Invest. 117:2051-2058.
9. De Luca, A., et al. 2008. The role of the EGFR signaling in tumor microenvironment. J. Cell. Physiol. 214:559-567.
10. Wen, X.F., et al. 2006. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene. 25:6986-6996.
11. Ciardiello, F., and Tortora, G. 2008. EGFR antagonists in cancer treatment. N. Engl. J. Med. 358:1160-1174.
12. Hudis, C.A. 2007. Trastuzumab - mechanism of action and use in clinical practice. N. Engl. J. Med. 357:39-51.
13. Britsch, S. 2007. The neuregulin-I/ErbB signaling system in development and disease. Adv. Anat. Embryol. Cell Biol. 190:1-65.
14. Yarden, Y., and Sliwkowski, M.X. 2001. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2:127-137.
15. Kuwai, T., et al. 2008. Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. Neoplasia. 10:489-500.
16. Bublil, E.M., and Yarden, Y. 2007. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr. Opin. Cell Biol. 19:124-134.
17. Mendelsohn, J., and Baselga, J. 2006. Epidermal growth factor receptor targeting in cancer. Semin. Oncol. 33:369-385.
18. Neve, R.M., Lane, H.A., and Hynes, N.E. 2001. The role of overexpressed HER2 in transformation. Ann. Oncol. 12:S9-S13.
19. Penuel, E., Akita, R.W., and Sliwkowski, M.X. 2002. Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association. J. Biol. Chem. 277:28468-28473.
20. Cai, C.Q., et al. 2008. Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations. Oncogene. 27:3201-3210.
21. Sarup, J., et al. 2008. Human EGF receptor (HER-1: HER-3) Fc-mediated heterodimer has broad anti-proliferative activity in vitro and in human tumor xenografts. Mol. Cancer Ther. 7:3223-3236.
22. Revillion, F., Lhotellier, V., Hornez, L., Bonneterre, J., and Peyrat, J.P. 2008. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann. Oncol. 19:73-80.
23. Stern, D.F. 2008. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J. Mammary Gland Biol. Neoplasia. 13:215-223.
24. Alimandi, M., et al. 1995. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene. 10:1813-1821.
25. Normanno, N., et al. 2005. The ErbB receptors and their ligands in cancer: an overview. Curr. Drug Targets. 6:243-257.
26. Zhan, L., Xiang, B., and Muthuswamy, S.K. 2006. Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors. Cancer Res. 66:5201-5208.
27. Gao, S.P., et al. 2007. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest. 117:3846-3856.
28. Schafer, Z.T., and Brugge, J.S. 2007. IL-6 involvement in epithelial cancers. J. Clin. Invest. 117:3660-3663.
29. Sasaki, T., et al. 2008. Modification of the primary tumor microenvironment by transforming growth factor alpha-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model. Am. J. Pathol. 173:205-216.
30. Weihua, Z., et al. 2008. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell. 13:385-393.
31. Bianchi, S., et al. 2006. ErbB-receptors expression and survival in breast carcinoma: a 15-year follow-up study. J. Cell. Physiol. 206:702-708.
32. Chow, N.H., Chan, S.H., Tzai, T.S., Ho, C.L., and Liu, H.S. 2001. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin. Cancer Res. 7:1957-1962.
33. Koutsopoulos, A.V., et al. 2007. Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome. Lung Cancer. 57:193-200.
34. Onn, A., et al. 2004. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin. Cancer Res. 10:136-143.
35. Wiseman, S.M., et al. 2005. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer. 103:1770-1777.
36. Reiman, J.M., Kmieciak, M., Manjili, M.H., and Knutson, K.L. 2007. Tumor immunoediting and immunosculpting pathways to cancer progression. Semin. Cancer Biol. 17:275-287.
37. Finn, O.J. 2008. Cancer immunology. N. Engl. J. Med. 358:2704-2715.
38. Urban, J.L., Shepard, H.M., Rothstein, J.L., Sugarman, B.J., and Schreiber, H. 1986. Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages. Proc. Natl. Acad. Sci. U. S. A. 83:5233-5237.
39. Sugarman, B.J., et al. 1985. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science. 230:943-945.
40. Sugarman, B.J., Lewis, G.D., Eessalu, T.E., Aggarwal, B.B., and Shepard, H.M. 1987. Effects of growth factors on the antiproliferative activity of tumor necrosis factors. Cancer Res. 47:780-786.
41. Hudziak, R.M., Schlessinger, J., and Ullrich, A. 1987. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl. Acad. Sci. U. S. A. 84:7159-7163.
42. Perantoni, A.O., Rice, J.M., Reed, C.D., Watatani, M., and Wenk, M.L. 1987. Activated neu oncogene sequences in primary tumors of the peripheral nervous system induced in rats by transplacental exposure to ethylnitrosourea. Proc. Natl. Acad. Sci. U. S. A. 84:6317-6321.
43. Coussens, L., et al. 1985. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 230:1132-1139.
44. Semba, K., Kamata, N., Toyoshima, K., and Yamamoto, T. 1985. A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc. Natl. Acad. Sci. U. S. A. 82:6497-6501.
45. King, C.R., Kraus, M.H., and Aaronson, S.A. 1985. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science. 229:974-976.
46. McGuire, W.L. 1987. Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res. Treat. 10:5-9.
47. Slamon, D.J., et al. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235:177-182.
48. van de Vijver, M., et al. 1987. Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol. Cell. Biol. 7:2019-2023.
49. Varley, J.M., Swallow, J.E., Brammar, W.J., Whittaker, J.L., and Walker, R.A. 1987. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene. 1:423-430.
50. Hudziak, R.M., et al. 1988. Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells. Proc. Natl. Acad. Sci. U. S. A. 85:5102-5106.
51. Wang, X., Chen, W., and Lin, Y. 2007. Sensitization of TNF-induced cytotoxicity in lung cancer cells by concurrent suppression of the NF-kappaB and Akt pathways. Biochem. Biophys. Res. Commun. 355:807-812.
52. Zhou, B.P., et al. 2000. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J. Biol. Chem. 275:8027-8031.
53. Su, W.P., et al. 2007. HER-2/neu raises SHP-2, stops IFN-gamma anti-proliferation in bladder cancer. Biochem. Biophys. Res. Commun. 356:181-186.
54. Wilson, C.A., et al. 2005. HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells. Breast Cancer Res. 7:R1058-R1079.
55. Fendly, B.M., et al. 1990. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 50:1550-1558.
56. Lewis, G.D., et al. 1993. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother. 37:255-263.
57. Hudziak, R.M., et al. 1989. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9:1165-1172.
58. Shepard, H.M., et al. 1991. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J. Clin. Immunol. 11:117-127.
59. Hudziak, R.M., Lewis, G.D., Holmes, W.E., Ullrich, A., and Shepard, H.M. 1990. Selection for transformation and met protooncogene amplification in NIH 3T3 fibroblasts using tumor necrosis factor alpha. Cell Growth Differ. 1:129-134.
60. Carter, P., et al. 1992. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 89:4285-4289.
61. Friedman, L.M., et al. 2005. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc. Natl. Acad. Sci. U. S. A. 102:1915-1920.
62. Nagy, P., et al. 1999. Activation-dependent clustering of the erbB2 receptor tyrosine kinase detected by scanning near-field optical microscopy. J. Cell Sci. 112:1733-1741.
63. Yang, S., et al. 2007. Mapping ErbB receptors on breast cancer cell membranes during signal transduction. J. Cell Sci. 120:2763-2773.
64. Varchetta, S., et al. 2007. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 67:11991-11999.
65. Musolino, A., et al. 2008. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26:1789-1796.
66. Ritter, C.A., et al. 2007. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin. Cancer Res. 13:4909-4919.
67. Barok, M., et al. 2008. Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. Cancer Lett. 260:198-208.
68. Li, Y.M., et al. 2004. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell. 6:459-469.
69. Britten, C.D. 2004. Targeting ErbB receptor signaling: a pan-ErbB approach to cancer. Mol. Cancer Ther. 3:1335-1342.
70. Hynes, N.E., Horsch, K., Olayioye, M.A., and Badache, A. 2001. The ErbB receptor tyrosine family as signal integrators. Endocr. Relat. Cancer. 8:151-159.
71. Daub, H., Weiss, F.U., Wallasch, C., and Ullrich, A. 1996. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature. 379:557-560.
72. Karnoub, A.E., and Weinberg, R.A. 2006. Chemokine networks and breast cancer metastasis. Breast Dis. 26:75-85.
73. Rozengurt, E. 2007. Mitogenic signaling pathways induced by G protein-coupled receptors. J. Cell. Physiol. 213:589-602.
74. Luppi, F., Longo, A.M., de Boer, W.I., Rabe, K.F., and Hiemstra, P.S. 2007. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. Lung Cancer. 56:25-33.
75. Murph, M., and Mills, G.B. 2007. Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression. Expert Rev. Mol. Med. 9:1-18.
76. Pastore, S., Mascia, F., Mariani, V., and Girolomoni, G. 2008. The epidermal growth factor receptor system in skin repair and inflammation. J. Invest. Dermatol. 128:1365-1374.
77. Pattarozzi, A., et al. 2008. 17beta-estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment. Mol. Pharmacol. 73:191-202.
78. Ohtsu, H., Dempsey, P.J., and Eguchi, S. 2006. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am. J. Physiol. Cell Physiol. 291:C1-C10.
79. Argast, G.M., Campbell, J.S., Brooling, J.T., and Fausto, N. 2004. Epidermal growth factor receptor transactivation mediates tumor necrosis factor-induced hepatocyte replication. J. Biol. Chem. 279:34530-34536.
80. Chen, W.N., et al. 2004. Induced autocrine signaling through the epidermal growth factor receptor contributes to the response of mammary epithelial cells to tumor necrosis factor alpha. J. Biol. Chem. 279:18488-18496.
81. Joo, C.K., et al. 2008. Ligand release-independent transactivation of epidermal growth factor receptor by transforming growth factor-beta involves multiple signaling pathways. Oncogene. 27:614-628.
82. Evdonin, A.L., Guzhova, I.V., Margulis, B.A., and Medvedeva, N.D. 2006. Extracellular heat shock protein 70 mediates heat stress-induced epidermal growth factor receptor transactivation in A431 carcinoma cells. FEBS Lett. 580:6674-6678.
83. Martin, M.U., and Wesche, H. 2002. Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family. Biochim. Biophys. Acta. 1592:265-280.
84. Hallbeck, A.L., Walz, T.M., Briheim, K., and Wasteson, A. 2005. TGF-alpha and ErbB2 production in synovial joint tissue: increased expression in arthritic joints. Scand. J. Rheumatol. 34:204-211.
85. Donepudi, M., and Resh, M.D. 2008. c-Src trafficking and co-localization with the EGF receptor promotes EGF ligand-independent EGF receptor activation and signaling. Cell Signal. 20:1359-1367.
86. Arora, P., Cuevas, B.D., Russo, A., Johnson, G.L., and Trejo, J. 2008. Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion. Oncogene. 27:4434-4445.
87. Chinni, S.R., et al. 2008. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol. Cancer Res. 6:446-457.
88. Walters, D.K., and Jelinek, D.F. 2004. A role for Janus kinases in crosstalk between ErbB3 and the interferon-alpha signaling complex in myeloma cells. Oncogene. 23:1197-1205.
89. Croce, C.M. 2008. Oncogenes and cancer. N. Engl. J. Med. 358:502-511.
90. Adams, C.W., et al. 2006. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol. Immunother. 55:717-727.
91. Hudelist, G., et al. 2003. Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res. Treat. 80:353-361.
92. Wheeler, D.L., et al. 2008. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene. 27:3944-3956.
93. Cai, Z., et al. 2008. Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185 (her2/neu) and the EGFR-p185 (her2/neu) complexes. Oncogene. 27:3870-3874.
94. Motoyama, A.B., Hynes, N.E., and Lane, H.A. 2002. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res. 62:3151-3158.
95. Sergina, N.V., et al. 2007. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 445:437-441.
96. Arpino, G., et al. 2007. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J. Natl. Cancer Inst. 99:694-705.
97. Franklin, M.C., et al. 2004. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 5:317-328.
98. Huang, G., Chantry, A., and Epstein, R.J. 1999. Overexpression of ErbB2 impairs ligand-dependent downregulation of epidermal growth factor receptors via a post-transcriptional mechanism. J. Cell. Biochem. 74:23-30.
99. Burstein, H.J., et al. 2008. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann. Oncol. 19:1068-1074.
100. Herbst, R.S., et al. 2007. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin. Cancer Res. 13:6175-6181.
101. Hynes, N.E. 2007. Targeting ERBB receptors in cancer. Recent Results Cancer Res. 172:45-57.
102. Reid, A., Vidal, L., Shaw, H., and de Bono, J. 2007. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur. J. Cancer. 43:481-489.
103. Fridman, J.S., et al. 2007. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin. Cancer Res. 13:1892-1902.
104. Fisher, J.F., and Mobashery, S. 2006. Recent advances in MMP inhibitor design. Cancer Metastasis Rev. 25:115-136.
105. Rocks, N., et al. 2008. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie. 90:369-379.
106. Tracey, D., Klareskog, L., Sasso, E.H., Salfeld, J.G., and Tak, P.P. 2008. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117:244-279.
107. Higashiyama, S., et al. 2008. Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands. Cancer Sci. 99:214-220.
108. Richman, S.A., et al. 2006. Development of a novel strategy for engineering high-affinity proteins by yeast display. Protein Eng. Des. Sel. 19:255-264.
109. Zhang, B., Karrison, T., Rowley, D.A., and Schreiber, H. 2008. IFN-g- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J. Clin. Invest. 118:1398-1404.
110. Zhang, B., et al. 2008. Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res. 68:1563-1571.
111. Fisk, B., Blevins, T.L., Wharton, J.T., and Ioannides, C.G. 1995. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med. 181:2109-2117.
112. Keogh, E., et al. 2001. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J. Immunol. 167:787-796.
113. Lustgarten, J., et al. 1997. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. Hum. Immunol. 52:109-118.
114. Lustgarten, J., Dominguez, A.L., and Cuadros, C. 2004. The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity. Eur. J. Immunol. 34:752-761.
115. Richman, S.A., and Kranz, D.M. 2007. Display, engineering, and applications of antigen-specific T cell receptors. Biomol. Eng. 24:361-373.
116. Schlange, T., Matsuda, Y., Lienhard, S., Huber, A., and Hynes, N.E. 2007. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res. 9:R63.
117. Prenzel, N., Zwick, E., Leserer, M., and Ullrich, A. 2000. Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: convergence point for signal integration and diversification. Breast Cancer Res. 2:184-190.